Increased glycolytic metabolism and PM2.5-activated DLAT overexpression have been shown to accelerate the development of non-small cell lung cancer, suggesting that DLAT may be the therapeutic marker of this type of cancer [37]. The gene discussed is DLAT; the disease is non-small cell lung carcinoma.